C-reactive protein in ischemic stroke and its etiologic subtypes

Journal of Stroke and Cerebrovascular Diseases

Volumn 12, Issue 2, 2003, Pages 74-81

  Eikelboom, John W ^a,b   Hankey, Graeme J ^a,b   Baker, Ross I ^a,b   McQuillan, Andrew ^a   Thom, Jim ^a   Staton, Janelle ^a   Cole, Vanessa ^a   Yi, Qilong ^c  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

C reactive protein; Cerebral infarction; Ischemic stroke; Pathophysiology; Stroke; Subtypes

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; EMBOLISM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; STROKE;

EID: 0344520207     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1053/jscd.2003.16     Document Type: Article

References (27)

1. Ridker PM. High sensitivity C-reactive protein. Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-1818.
2. Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischaemic stroke and transient ischaemic attack. The Framingham Study. Stroke 2001;32:2575-2579.
3. Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor. More than an epiphenomenon? Circulation 1999;100:96-102.
4. Weintraub WS, Harrison DG. C-reactive protein, inflammation and atherosclerosis: do we really understand it. Eur Heart J 2000;21:958-960.
5. Yeh ETH, Anderson V, Pasceri V, et al. C-reactive protein. Linking inflammation to cardiovascular complications. Circulation 2001;104:974-975.
6. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-2168.
7. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2094-2099.
8. Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently co-localizes with the terminal complement complex in the intima of early atherosclerotic lesions in human coronary arteries. Arterioscler Thromb Vasc Biol 1998;18:1386-1392.
9. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages. Implications for atherosclerosis. Circulation 2001;103:1194-1197.
10. Danesh J, Whincup P, Walker M, et al. Low-grade inflammation and coronary heart disease: prospective study and updated meta-analysis. BMJ 2000;321:199-204.
11. Muir KW, Weir CJ, Alwan W, et al. C-reactive protein and outcome after ischaemic stroke. Stroke 1999;30:981-985.
12. Gussekloo J, Schaap MC, Frolich M, et al. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol 2000;20:1047-1051.
13. Ford ES, Giles WH. Serum C-reactive protein and self-reported stroke. Findings from the Third National Health and Nutrition Examination Survey. Arterioscler Thromb Vasc Biol 2000;20:1052-1056.
14. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischaemic stroke. Stroke 2001;32:133-138.
15. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischaemic stroke: an independent prognostic factor. Stroke 2001;32:917-924.
16. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126.
17. Beamer NB, Coull BM, Clark WM, et al. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol 1995;37:800-805.
18. Murat Sumer M, Erturk O. Ischemic stroke subtypes: risk factors, functional outcome and recurrence. Neurol Sci 2002;22:449-454.
19. Petty GW, Brown RD, Whisnant JP, et al. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000;31:1062-1068.
20. Bamford JM, Sandercock PAG, Warlow CP, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1989;20:828.
21. Wade DT, Collin C. The Barthel ADL Index: a standard measure of physical disability? Int Disabil Stud 1988;10:64-67.
22. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976;54:541-553.
23. Warlow CP, Dennis MS, van Gijn J, et al. Stroke: A Practical Guide to Management. Blackwell Scientific Productions, Oxford, UK, 1996.
24. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999;106:506-512.
25. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
26. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentrations of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-235.
27. Beamer NB, Coull BM, Clark WM, et al. Persistent inflammatory response in stroke survivors. Neurology 1998;50:1722-1728.